We're delighted that abiraterone will now be available to men
regardless of where they live in the UK. Initially the drug was
rejected for use on the NHS, but in 2012 the National
Institute for Health and Care Excellence (NICE)
reversed its draft decision for England and Wales, the
Health Department in Northern Ireland endorsed this decision, and
the Scottish Medicines Consortium (SMC) followed suit.
This is great news for men with advanced prostate cancer and a
major victory for Prostate Cancer UK's campaign.
Thank you to all our supporters, men with prostate cancer
and their families, health professionals and politicians who helped
with this campaign.